Can Blinatumomab be reimbursed by medical insurance?

Blinatumomab (Blinatumomab) The original drug is already on the market for sale in China and is not currently covered by medical insurance. Patients who need to use this drug for treatment can only purchase it at their own expense and cannot use the national medical insurance for reimbursement. Belintuzumab, sold under the brand nameBlincyto, is indicated for the treatment of adults and children with relapsed or refractoryCD19-positive B-cell precursor acute lymphoblastic leukemia (ALL); it is also indicated for the treatment of adults and children with CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL) in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1%.